Invivyd doses first participants in Phase 3 COVID-19 trial

Invivyd Inc (NASDAQ:IVVD) has dosed the first participants in its LIBERTY Phase 3 trial, a study testing the company's ...
Nasdaq

Invivyd, Inc. Announces NCCN Guidelines Update: Monoclonal Antibodies Recommended for COVID-19 Prophylaxis in Cancer Patients

The updated NCCN Guidelines now include the recommendation for monoclonal antibodies for pre-exposure prophylaxis against COVID-19, highlighting the significance of Invivyd's products in cancer care.
Business Wire

VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today ...

Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial

Latest Modification is Important Required Step to Releasing 12-month Data from 400-participant Sentinel Cohort Funding to Advance Data Analysis from More Than 5,000 Trial Participants Ahead of Key ...
Hosted on MSN

Invivyd, Inc. (IVVD) Secures FDA Path for COVID-19 Antibody Approval

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Invivyd, Inc. stands among them. Invivyd, Inc. (NASDAQ:IVVD) is a commercial-stage ...
Nasdaq

AIM ImmunoTech Inc. Highlights Study Linking COVID-19 to Increased Risk of ME/CFS and Ampligen's Potential as a Therapeutic Solution

A study links COVID-19 infection to higher ME/CFS rates, supporting Ampligen's potential as a treatment for affected individuals. AIM ImmunoTech Inc. has commented on a recently published study in the ...
EurekAlert!

CastleVax Inc. receives BARDA project NextGen award valued at up to $338 million to advance intranasal NDV-based COVID-19 booster vaccine into phase 2b clinical efficacy testing

CastleVax, a clinical stage vaccine platform company, has received a Project NexGen award valued at up to $338 million from the Biomedical Advanced Research and Development Authority (BARDA), part of ...